Although CD157 was initially characterized as a stromal [10] and myeloid surface glycoprotein [11] involved in the control of cell migration and diapedesis [12], we recently demonstrated that CD157 is also expressed by >90% of primary EOC and that high levels of CD157 are associated with rapid tumor relapse in patients with EOC. This evidence concerns the gene BST1 and neoplasm.